• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从数百万化合物库中快速鉴定潜在药物候选物。二维相似性搜索与三维配体/结构的方法相结合,并进行体外筛选。

Rapid Identification of Potential Drug Candidates from Multi-Million Compounds' Repositories. Combination of 2D Similarity Search with 3D Ligand/Structure Based Methods and In Vitro Screening.

机构信息

TargetEx Ltd., Madách I. u. 31/2, 2120 Dunakeszi, Hungary.

出版信息

Molecules. 2021 Sep 15;26(18):5593. doi: 10.3390/molecules26185593.

DOI:10.3390/molecules26185593
PMID:34577064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8468386/
Abstract

Rapid in silico selection of target focused libraries from commercial repositories is an attractive and cost-effective approach in early drug discovery. If structures of active compounds are available, rapid 2D similarity search can be performed on multimillion compounds' databases. This approach can be combined with physico-chemical parameter and diversity filtering, bioisosteric replacements, and fragment-based approaches for performing a first round biological screening. Our objectives were to investigate the combination of 2D similarity search with various 3D ligand and structure-based methods for hit expansion and validation, in order to increase the hit rate and novelty. In the present account, six case studies are described and the efficiency of mixing is evaluated. While sequentially combined 2D/3D similarity approach increases the hit rate significantly, sequential combination of 2D similarity with pharmacophore model or 3D docking enriched the resulting focused library with novel chemotypes. Parallel integrated approaches allowed the comparison of the various 2D and 3D methods and revealed that 2D similarity-based and 3D ligand and structure-based techniques are often complementary, and their combinations represent a powerful synergy. Finally, the lessons we learnt including the advantages and pitfalls of the described approaches are discussed.

摘要

从商业库中快速进行针对目标的虚拟库选择是早期药物发现中一种有吸引力且具有成本效益的方法。如果有活性化合物的结构,则可以在数百万种化合物的数据库上进行快速的 2D 相似性搜索。这种方法可以与物理化学参数和多样性过滤、生物等排替换以及基于片段的方法结合使用,以进行第一轮生物筛选。我们的目标是研究 2D 相似性搜索与各种 3D 配体和基于结构的方法相结合,以进行命中扩展和验证,从而提高命中率和新颖性。在本报告中,描述了六个案例研究,并评估了混合的效率。虽然顺序组合的 2D/3D 相似性方法显著提高了命中率,但与药效团模型或 3D 对接的顺序组合使所得的聚焦库中富含新型化学型。并行集成方法允许比较各种 2D 和 3D 方法,并表明基于 2D 相似性的方法和基于 3D 配体和结构的技术通常是互补的,它们的组合代表了强大的协同作用。最后,讨论了我们所学到的经验教训,包括所描述方法的优点和缺点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/3780dc02155b/molecules-26-05593-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/32f6774f8041/molecules-26-05593-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/7a3bd44e46a0/molecules-26-05593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/fd3e8fc2095f/molecules-26-05593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/6cbc1a746d9d/molecules-26-05593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/eafb7dfa4e1b/molecules-26-05593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/815414495e8b/molecules-26-05593-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/ea05a6a7b81d/molecules-26-05593-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/b7f5e576a63f/molecules-26-05593-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/15068bf9d878/molecules-26-05593-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/eb2e05d3299c/molecules-26-05593-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/4b33c583f6c9/molecules-26-05593-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/28e163f48871/molecules-26-05593-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/46b9c85c80b9/molecules-26-05593-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/30bc986d21b9/molecules-26-05593-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/aa8a214156dd/molecules-26-05593-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/8ab8091f3879/molecules-26-05593-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/22158beaa16d/molecules-26-05593-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/3f9b754f0f00/molecules-26-05593-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/3780dc02155b/molecules-26-05593-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/32f6774f8041/molecules-26-05593-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/7a3bd44e46a0/molecules-26-05593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/fd3e8fc2095f/molecules-26-05593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/6cbc1a746d9d/molecules-26-05593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/eafb7dfa4e1b/molecules-26-05593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/815414495e8b/molecules-26-05593-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/ea05a6a7b81d/molecules-26-05593-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/b7f5e576a63f/molecules-26-05593-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/15068bf9d878/molecules-26-05593-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/eb2e05d3299c/molecules-26-05593-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/4b33c583f6c9/molecules-26-05593-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/28e163f48871/molecules-26-05593-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/46b9c85c80b9/molecules-26-05593-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/30bc986d21b9/molecules-26-05593-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/aa8a214156dd/molecules-26-05593-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/8ab8091f3879/molecules-26-05593-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/22158beaa16d/molecules-26-05593-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/3f9b754f0f00/molecules-26-05593-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab2c/8468386/3780dc02155b/molecules-26-05593-g019.jpg

相似文献

1
Rapid Identification of Potential Drug Candidates from Multi-Million Compounds' Repositories. Combination of 2D Similarity Search with 3D Ligand/Structure Based Methods and In Vitro Screening.从数百万化合物库中快速鉴定潜在药物候选物。二维相似性搜索与三维配体/结构的方法相结合,并进行体外筛选。
Molecules. 2021 Sep 15;26(18):5593. doi: 10.3390/molecules26185593.
2
Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5-HT6 Antagonists from Large Commercial Repositories.结合药效团匹配、二维相似性搜索和体外生物学测定从大型商业化合物库中筛选潜在的5-HT6拮抗剂
Chem Biol Drug Des. 2015 Oct;86(4):864-80. doi: 10.1111/cbdd.12563. Epub 2015 Apr 30.
3
Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation.将 2D 和 3D 计算方法相结合,从数百万种化合物库中快速筛选潜在的 PDE5 抑制剂:生物学评价。
Mol Divers. 2012 Feb;16(1):59-72. doi: 10.1007/s11030-011-9335-0. Epub 2011 Sep 27.
4
Combination of 2D/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors.二维/三维配体相似性搜索在从数百万化合物库中快速虚拟筛选中的结合。潜在 PDE4 和 PDE5 抑制剂的筛选和生物学评价。
Molecules. 2014 May 28;19(6):7008-39. doi: 10.3390/molecules19067008.
5
Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity.配体骨架跃迁结合 3D 最大子结构搜索和分子相似性。
BMC Bioinformatics. 2009 Aug 11;10:245. doi: 10.1186/1471-2105-10-245.
6
[Selection of a melanine concentrating hormone receptor-1 (MCHR1) antagonists' focused library and its biological screening with AequoScreen].[黑色素浓缩激素受体-1(MCHR1)拮抗剂聚焦文库的筛选及其AequoScreen生物筛选]
Acta Pharm Hung. 2013;83(3):71-87.
7
Towards the chemoinformatic-based identification of DNA methyltransferase inhibitors: 2D- and 3D-similarity profile of screening libraries.迈向基于化学信息学的DNA甲基转移酶抑制剂鉴定:筛选文库的二维和三维相似性概况
Curr Comput Aided Drug Des. 2012 Dec 1;8(4):317-29. doi: 10.2174/157340912803519606.
8
The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience.瑞士相似度 2021 网络工具:新型化学库和其他方法,用于增强基于配体的虚拟筛选体验。
Int J Mol Sci. 2022 Jan 12;23(2):811. doi: 10.3390/ijms23020811.
9
Fragment-Based Drug Design of Selective HDAC6 Inhibitors.选择性组蛋白去乙酰化酶6(HDAC6)抑制剂的基于片段的药物设计
Methods Mol Biol. 2021;2266:155-170. doi: 10.1007/978-1-0716-1209-5_9.
10
Design and Selection of Novel C1s Inhibitors by In Silico and In Vitro Approaches.通过计算机模拟和体外实验方法设计和选择新型 C1s 抑制剂。
Molecules. 2019 Oct 9;24(20):3641. doi: 10.3390/molecules24203641.

引用本文的文献

1
Screening of Potential Drug Targets Based on the Genome-Scale Metabolic Network Model of .基于……的基因组规模代谢网络模型筛选潜在药物靶点
Curr Issues Mol Biol. 2025 Jul 21;47(7):575. doi: 10.3390/cimb47070575.
2
Importance of Computer-aided Drug Design in Modern Pharmaceutical Research.计算机辅助药物设计在现代药物研究中的重要性。
Curr Drug Discov Technol. 2025;22(3):e15701638361318. doi: 10.2174/0115701638361318241230073123.
3
Using alternative SMILES representations to identify novel functional analogues in chemical similarity vector searches.

本文引用的文献

1
Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease.对暗化学物质和食品化学物质进行的共识虚拟筛选发现了严重急性呼吸综合征冠状病毒2主蛋白酶的潜在抑制剂。
RSC Adv. 2020 Jul 1;10(42):25089-25099. doi: 10.1039/d0ra04922k. eCollection 2020 Jun 29.
2
Merging Ligand-Based and Structure-Based Methods in Drug Discovery: An Overview of Combined Virtual Screening Approaches.将基于配体和基于结构的方法合并用于药物发现:联合虚拟筛选方法概述。
Molecules. 2020 Oct 15;25(20):4723. doi: 10.3390/molecules25204723.
3
Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening.
在化学相似性向量搜索中使用替代的SMILES表示法来识别新型功能类似物。
Patterns (N Y). 2023 Oct 30;4(12):100865. doi: 10.1016/j.patter.2023.100865. eCollection 2023 Dec 8.
4
Repurposing Drugs for Inhibition against ALDH2 via a 2D/3D Ligand-Based Similarity Search and Molecular Simulation.通过二维/三维基于配体相似性搜索和分子模拟的 ALDH2 抑制药物再利用。
Molecules. 2023 Oct 29;28(21):7325. doi: 10.3390/molecules28217325.
通过大规模虚拟筛选鉴定出的新型组蛋白去乙酰化酶抑制剂和HIV-1潜伏逆转剂。
Front Pharmacol. 2020 Jun 17;11:905. doi: 10.3389/fphar.2020.00905. eCollection 2020.
4
Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.虚拟筛选、ADME/Tox 预测和老药再利用概念,以用于对抗 COVID-19 的未来用途。
Life Sci. 2020 Sep 1;256:117963. doi: 10.1016/j.lfs.2020.117963. Epub 2020 Jun 11.
5
Peptide-like and small-molecule inhibitors against Covid-19.针对新冠病毒的肽类和小分子抑制剂。
J Biomol Struct Dyn. 2021 May;39(8):2904-2913. doi: 10.1080/07391102.2020.1757510. Epub 2020 May 6.
6
Identification of natural products as selective PTP1B inhibitors via virtual screening.通过虚拟筛选鉴定天然产物作为选择性 PTP1B 抑制剂。
Bioorg Chem. 2020 May;98:103706. doi: 10.1016/j.bioorg.2020.103706. Epub 2020 Mar 5.
7
Applying Machine Learning to Ultrafast Shape Recognition in Ligand-Based Virtual Screening.将机器学习应用于基于配体的虚拟筛选中的超快形状识别。
Front Pharmacol. 2020 Feb 19;10:1675. doi: 10.3389/fphar.2019.01675. eCollection 2019.
8
Methods for Design of Kinase Inhibitors as Anticancer Drugs.激酶抑制剂作为抗癌药物的设计方法。
Front Chem. 2020 Jan 8;7:873. doi: 10.3389/fchem.2019.00873. eCollection 2019.
9
Virtual screening-driven discovery of dual 5-HT/5-HT receptor ligands with pro-cognitive properties.基于虚拟筛选的具有认知增强特性的双重 5-HT/5-HT 受体配体的发现。
Eur J Med Chem. 2020 Jan 1;185:111857. doi: 10.1016/j.ejmech.2019.111857. Epub 2019 Nov 7.
10
Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing.CANDO指纹识别:基于结构和配体的散弹枪式药物重新利用提高准确性
ACS Omega. 2019 Oct 9;4(17):17393-17403. doi: 10.1021/acsomega.9b02160. eCollection 2019 Oct 22.